Five-year angiographic, OCT and clinical outcomes of a randomized comparison of everolimus and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
Sara SchukraftDiego ArroyoMario TogniJean-Jacques GoyPeter WenaweserMathieu StadelmannGerard BaeriswylOlivier MullerJean-Christophe StaufferSerban PuricelStéphane CookPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)
Five-year clinical outcomes were similar between BVS and DES patients as well as angiographic outcomes in a selected subgroup. However, a definitive conclusion cannot be drawn because the EverBio-2 trial was not powered for clinical and angiographic endpoints at 5 years of follow-up.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- coronary artery
- phase iii
- coronary artery disease
- clinical trial
- peritoneal dialysis
- adipose tissue
- heart failure
- type diabetes
- squamous cell carcinoma
- patient reported outcomes
- metabolic syndrome
- randomized controlled trial
- aortic stenosis
- skeletal muscle
- phase ii
- insulin resistance
- tissue engineering
- atrial fibrillation